PT  - JOURNAL ARTICLE
AU  - Matthew C. Woodruff
AU  - Richard P. Ramonell
AU  - F. Eun-Hyung Lee
AU  - Ignacio Sanz
TI  - Broadly-targeted autoreactivity is common in severe SARS-CoV-2 Infection
AID  - 10.1101/2020.10.21.20216192
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.21.20216192
4099  - http://medrxiv.org/content/early/2020/10/23/2020.10.21.20216192.short
4100  - http://medrxiv.org/content/early/2020/10/23/2020.10.21.20216192.full
AB  - Severe SARS-CoV-2 infection is linked to the presence of autoantibodies against multiple targets, including phospholipids and type-I interferons. We recently identified activation of an autoimmune-prone B cell response pathway as correlate of severe COVID-19, raising the possibility of de novo autoreactive antibody production during the antiviral response. Here, we identify autoreactive antibodies as a common feature of severe COVID-19, identifying biomarkers of tolerance breaks that may indicate aggressive immunomodulation.Competing Interest StatementDr. Lee is the founder of MicroB-plex, Inc and has research grants with Genentech.Funding StatementThis work was supported by National Institutes of Health grants: UL TR000424 (Emory Library IT), U19-AI110483 Emory Autoimmunity Center of Excellence (I.S.), P01-AI125180-01 (I.S., F.E.L.), R37-AI049660 (I.S.), 1R01AI121252 (F.E.L.), 1U01AI141993 (F.E.L), and T32-HL116271-07 (R.P.R.)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All research was approved by the Emory University Institutional Review Board (Emory IRB numbers IRB00058507, IRB00057983, and IRB00058271) and was performed in accordance with all relevant guidelines and regulations. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRelevant data will be made available as necessary following peer-review